We were delighted to catch up with Dr Qi Cui (Scheie Eye Institute, University of Pennsylvania, PA, USA), who told us about her research on the GLP-1R agonist NLY01 and the next steps for clinical development.
- What is NLY01 and what is the rationale for its use in glaucoma therapy? (00:20)
- Could you give us an overview of your study and its findings? (01:31)
- What will be the next steps in the clinical development of NLY01? (02:46)
Speaker Disclosure: Qi Cui discloses the following: Patent (pending): Penn Center for Innovation; Sponsored Research: Neuraly, Inc., NIH/NEI K08EY029765.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of AGS 2021.
Share this Video
Related Videos In Glaucoma
Ticiana De Francesco, AGS 2023: Corneal endothelial cell safety profile of three different MiGS stents
Endothelial cell safety is an important factor to consider when selecting early surgical treatment for glaucoma patients. It was a pleasure to speak with Dr Ticiana De Francesco (Hospital de Olhos Leiria de Andrade (HOLA) Fortaleza, Brazil) around her study on comparing the effect of cataract surgery and iStent inject, Hydrus micro-stent, or CyPass micro-stent […]
Ticiana De Francesco, AGS 2023: Minimally invasive glaucoma surgery (MiGS) devices in glaucoma management
Minimally invasive glaucoma surgery (MiGS) devices have revolutionised in glaucoma management, achieving reliable IOP reduction with a favorable safety profile and quick postoperative recovery. It was a pleasure to speak with Dr Ticiana De Francesco (Hospital de Olhos Leiria de Andrade (HOLA) Fortaleza, Brazil) to find out her thoughts in the current status of minimally invasive glaucoma […]
Luis Abegão Pinto: World Glaucoma Week 2023
World Glaucoma Week kicks off on 12 March, 2023, with the aim of raising awareness of the impact of this devastating disease. The key to preventing needless vision impairment is prompt diagnosis and treatment. However, many are unaware they have the disease or do not have access to much-needed care. This is particularly true in […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!